Biologics for rheumatoid arthritis: an overview of Cochrane reviews
about
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisBiologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisBalneotherapy (or spa therapy) for rheumatoid arthritisInterventions for treating hospital-acquired pneumonia: an overview of Cochrane systematic reviewsInterventions for treating community-acquired pneumonia: an overview of Cochrane systematic reviewsCertolizumab pegol (CDP870) for rheumatoid arthritis in adultsDown titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activityErythropoiesis-stimulating agents for anemia in rheumatoid arthritisFolic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritisInterventions for treating community-acquired pneumonia: an overview of Cochrane systematic reviewsInterventions for treating hospital-acquired pneumonia: an overview of Cochrane systematic reviewsAdverse effects of biologics: a network meta-analysis and Cochrane overviewHerbal therapy for treating rheumatoid arthritisOverview of systematic reviews - a new type of study. Part IIExperiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services.Big data and systematic reviews in nutritional epidemiology.Methodology in conducting a systematic review of systematic reviews of healthcare interventionsOverview of systematic reviews - a new type of study: part I: why and for whom?Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritisMethodological overview of systematic reviews to establish the evidence base for emergency general surgery.Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective.German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment.[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis].
P2860
Q21134808-61A209B4-9367-494E-8F22-80211A5C3B15Q24185797-B87080AD-53DE-4B91-88B1-816F82134C9EQ24186540-0945E051-2836-4788-8CF2-8E58BD9C28CDQ24193394-06202F8D-5D35-421B-A1BF-A12A63E3C5C1Q24193397-AB2B29FC-30CF-4EA9-8233-5540534F615AQ24193535-55487A89-F1D3-455E-998D-EFB5050DB5BEQ24198056-98C9F4D4-32BC-45F1-9859-FF031A4F8A6AQ24200775-A8F0083C-1B8C-432E-AF5E-1128F1D16A56Q24202950-A19AF780-9650-4890-BFA3-49CC14DCDEF4Q24234146-F294A82B-70F5-47E6-B5E7-0C1BFB16F56EQ24234157-FAC0967E-251E-4D93-ACE5-7639580CD304Q24235218-F457DBFF-6244-4429-B63C-02DF0B4F695AQ24236611-BED8A46C-E7B2-4B7E-A1F8-3262843B163DQ26862742-22CDFAC4-D954-4B55-83BC-C6FBD45A3278Q30842186-6EF23344-FC33-489E-A250-C58126914898Q30870465-8F525837-48AE-469F-AAF3-2A233D11DAA9Q33811344-7D014D31-AA64-4B2F-94C8-BF9704B2854BQ34323697-ABBA3C26-E12F-4B69-9747-B96EEF5FD2A8Q34338355-B1A103E1-EF1E-4BF0-9711-4A88FD44EF39Q36603223-C5392FB4-B457-4F0E-9430-7D8343ABA311Q37717956-9A9129D3-E979-483D-A82E-7C77E58E4CC6Q38102726-7CB357E3-8A0E-4B2D-9345-FB9717E07E11Q38128726-DC700B5C-DEF9-45E8-8841-2E4E229DEF50Q39885959-78A7FCBA-3D20-4986-9B6D-322F926AC70AQ41601731-C75097CD-2A74-462B-AE65-26183470D3B8Q45093232-B772F94E-6BA5-4F7E-9DA6-6F5DFB7A7D72Q50916784-5EEFA77F-F967-4AD8-8148-C10981C713EAQ52887079-945E6781-7136-48A4-BC2C-1D884B9084C2
P2860
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@en
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@en-gb
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@nl
type
label
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@en
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@en-gb
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@nl
prefLabel
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@en
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@en-gb
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@nl
P2093
P2860
P50
P1476
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
@en
P2093
George A Wells
Maria E Suarez-Almazor
Robin Christensen
P2860
P356
10.1002/14651858.CD007848
P50
P577
2009-04-15T00:00:00Z